---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001491"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T17:21:37.620328+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Aptose regains Nasdaq minimum bid price compliance; equity rule still breached

## Summary
- Nasdaq confirmed closing bid price at or above $1.00 for 10 consecutive business days as of March 14, 2025.
- Aptose remains non-compliant with Nasdaq's $2.5M shareholders' equity requirement.
- Company operates under a Hearing Panel exception to regain equity compliance, but no assurance of success.
- Aptose is a clinical-stage precision oncology firm developing tuspetinib-based triple therapy for newly diagnosed AML.

## SEC filing metadata
- accession: 0001171843-25-001491
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325001491/0001171843-25-001491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325001491/f8k_031725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001491
- JSON: https://secwatch.observer/filing/0001171843-25-001491.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001491.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.